Searching for Biomarkers of IFNβ Activity in Multiple Sclerosis Patients
Author Information
Author(s): Malhotra Sunny, Bustamante Marta F., Pérez-Miralles Francisco, Rio Jordi, Ruiz de Villa Mari Carmen, Vegas Esteban, Nonell Lara, Deisenhammer Florian, Fissolo Nicolás, Nurtdinov Ramil N., Montalban Xavier, Comabella Manuel
Primary Institution: Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d′Hebron, Barcelona, Spain
Hypothesis
Can specific biomarkers of IFNβ bioactivity be identified in patients with Multiple Sclerosis?
Conclusion
The study proposes specific biomarkers that may be used alongside MxA to evaluate IFNβ bioactivity and their potential role in MS pathogenesis.
Supporting Evidence
- Nine genes were identified that followed similar expression patterns to the MX1 gene.
- USP18 was significantly induced at lower IFNβ concentrations compared to MX1.
- USP18 expression was found to be deficient in MS patients compared to healthy controls.
Takeaway
Researchers looked for special markers in blood that show how well a medicine works for people with Multiple Sclerosis.
Methodology
Gene expression microarrays were performed on PBMC from MS patients treated with IFNβ, comparing those with and without neutralizing antibodies.
Potential Biases
Potential bias in patient selection and the influence of treatment history on biomarker expression.
Limitations
The study primarily focused on a small sample size and specific biomarkers, which may not represent all patients with MS.
Participant Demographics
14 untreated RRMS patients, mean age 42.1 years, 64.3% females.
Statistical Information
P-Value
p=0.0004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website